Hutchison China MediTech Limited (NASDAQ:HCM) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

Separately, Canaccord Genuity set a $30.00 target price on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a report on Monday, July 31st.

Shares of Hutchison China MediTech Limited (NASDAQ:HCM) opened at 30.20 on Thursday. The stock’s 50 day moving average is $26.52 and its 200 day moving average is $26.52. Hutchison China MediTech Limited has a 1-year low of $10.61 and a 1-year high of $32.03.

TRADEMARK VIOLATION WARNING: “Hutchison China MediTech Limited (HCM) Upgraded to Strong-Buy at BidaskClub” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/05/hutchison-china-meditech-limited-hcm-upgraded-to-strong-buy-at-bidaskclub.html.

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in Hutchison China MediTech Limited during the 1st quarter worth $618,000. The Manufacturers Life Insurance Company boosted its stake in Hutchison China MediTech Limited by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock worth $2,420,000 after purchasing an additional 7,400 shares during the period. Baillie Gifford & Co. boosted its stake in Hutchison China MediTech Limited by 2.7% during the 1st quarter. Baillie Gifford & Co. now owns 157,892 shares of the company’s stock worth $3,150,000 after purchasing an additional 4,189 shares during the period. JPMorgan Chase & Co. acquired a new stake in Hutchison China MediTech Limited during the 2nd quarter worth $5,102,000. Finally, Wellington Management Group LLP boosted its stake in Hutchison China MediTech Limited by 7.4% during the 1st quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after purchasing an additional 35,053 shares during the period. Hedge funds and other institutional investors own 4.06% of the company’s stock.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.